Video

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.


Seema A. Bhat, MD, hematologist, The Ohio State University Comprehensive Cancer Center–James, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia (CLL).

With the introduction of targeted therapy, CLL continues to be a rapidly evolving field, says Bhat.

Targeted therapies are given indefinitely, which can add toxicity and financial burden and decrease compliance, Bhat explains.

 

However, combining targeted agents may induce better and deeper remissions, which could allow for time-limited options, says Bhat.


Time-limited combinations could reduce the long-term adverse effects and financial toxicity that are associated with indefinite treatment, concludes Bhat.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.